Kervran A, Blache P, Bataille D
Endocrinology. 1987 Aug;121(2):704-13. doi: 10.1210/endo-121-2-704.
Oxyntomodulin (OXM), an intestinal glucagon-containing peptide extended at its C-terminal end by an octa-peptide, is one of the gut glucagon-like immunoreactants (GLI) or enteroglucagon. The distribution of OXM and glucagon was determined in the gastrointestinal tract and in the plasma of the rat. Reversed-phase HPLC, associated with RRA or RIA, performed with an N-terminally directed glucagon antiserum (GOL), was used. HPLC of intestinal extracts or plasma separated the GOL immunoreactivity into three peaks: two major peaks coeluting with a preparation of rat glicentin (peak I, partially purified from rat intestine) and porcine or rat OXM, respectively, and a smaller peak coeluting with glucagon. The behavior of the three peaks in the analytical systems matched that of glicentin, OXM, and glucagon, respectively, allowing their identification. The concentrations of OXM picomoles per g of tissue) gradually increased from the duodenum (9 +/- 1) to ileum (93 +/- 4), thereafter decreasing in cecum and colon (22 +/- 3). In the gut, OXM, glucagon, and peak I averaged 40%, 1%, and 59% of the total GLI, respectively. OXM was present in significant amounts in the pancreas (18% of GLI) and stomach (27% of GLI), two tissues in which it accounted, together with glucagon, for almost the totality of GLI. In 24 h-fasted rats, plasma concentrations of OXM, glucagon, and peak I, determined after HPLC with GOL antiserum, were 15.1 pM, 8.6 pM, and 12.3 pM, respectively. Two hours after refeeding, both OXM and peak I were significantly increased (P less than 0.05 and P less than 0.02) by a similar factor (2-fold), while glucagon remained unchanged. When the HPLC results were compared with RIA measurement of GLI (GOL antiserum) and glucagon (with a C-terminal glucagon antiserum) in plasma, enteroglucagon (GOL--C-terminal glucagon antiserum immunoreactivities) correlated well with the sum of OXM plus peak I. The combination of HPLC and RRA or RIA allows the unambiguous determination of OXM, glucagon, and glicentin (peak I) in tissues and plasma. In the rat intestine and in the plasma, OXM and glicentin appear roughly in the same ratio and seem to be the major components, if not the totality, of enteroglucagon.
胃泌酸调节素(OXM)是一种在其C末端延伸有一个八肽的含肠胰高血糖素的肽,是肠道胰高血糖素样免疫反应物(GLI)或肠胰高血糖素之一。在大鼠的胃肠道和血浆中测定了OXM和胰高血糖素的分布。使用与RRA或RIA相关的反相HPLC,用N末端导向的胰高血糖素抗血清(GOL)进行。肠道提取物或血浆的HPLC将GOL免疫反应性分离为三个峰:两个主要峰分别与大鼠甘丙素(峰I,从大鼠肠道部分纯化)和猪或大鼠OXM的制剂共洗脱,一个较小的峰与胰高血糖素共洗脱。这三个峰在分析系统中的行为分别与甘丙素、OXM和胰高血糖素的行为相匹配,从而得以鉴定。每克组织中OXM的浓度(皮摩尔数)从十二指肠(9±1)逐渐增加到回肠(93±4),此后在盲肠和结肠中降低(22±3)。在肠道中,OXM、胰高血糖素和峰I分别平均占总GLI的40%、1%和59%。OXM在胰腺(占GLI的18%)和胃(占GLI的27%)中大量存在,在这两个组织中,它与胰高血糖素一起几乎占了GLI的全部。在禁食24小时的大鼠中,用GOL抗血清进行HPLC后测定的血浆中OXM、胰高血糖素和峰I的浓度分别为15.1 pM、8.6 pM和12.3 pM。重新喂食两小时后,OXM和峰I均显著增加(P<0.05和P<0.02),增加倍数相似(2倍),而胰高血糖素保持不变。当将HPLC结果与血浆中GLI(GOL抗血清)和胰高血糖素(用C末端胰高血糖素抗血清)的RIA测量结果进行比较时,肠胰高血糖素(GOL - C末端胰高血糖素抗血清免疫反应性)与OXM加峰I的总和相关性良好。HPLC与RRA或RIA的结合能够明确测定组织和血浆中的OXM、胰高血糖素和甘丙素(峰I)。在大鼠肠道和血浆中,OXM和甘丙素的比例大致相同,似乎是肠胰高血糖素的主要成分,如果不是全部成分的话。